Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

US Doctor Warns Against Backlash to Gene-Edited Baby Claim

By Marilynn Marchione, AP Chief Medical Writer | November 28, 2018

(AP Photo/Mark Schiefelbein)

HONG KONG (AP) — A prominent American scientist is warning against a backlash to the claim that a Chinese scientist has helped make the world’s first gene-edited babies.

Harvard Medical School dean Dr. George Daley says it would be unfortunate if a misstep with a first case led scientists and regulators to reject the good that could come from altering DNA to treat or prevent diseases.

Daley spoke Wednesday at an international conference in Hong Kong, where the Chinese scientist, He Jiankui of Shenzhen, also is scheduled to speak.

He says his lab used the powerful gene-editing tool CRISPR to alter the DNA of human embryos to try to help them resist possible future infection with the AIDS virus. He said twin girls with the altered genes were born earlier this month.

There is not yet independent confirmation of his claim, but scientists and regulators have been swift to condemn the experiment as unethical and unscientific.

The National Health Commission has ordered local officials in Guangdong province to investigate He’s actions, and his employer, Southern University of Science and Technology, is investigating as well.

The Chinese researcher said he practiced editing mice, monkey, and human embryos in the lab for several years and has applied for patents on his methods.

He said he chose embryo gene editing for HIV because these infections are a big problem in China. He sought to disable a gene called CCR5 that forms a protein doorway that allows HIV, the virus that causes AIDS, to enter a cell.

Related Articles Read More >

This is the logo of Novartis.
Novartis opens new manufacturing plant in California
Coriolis meter options for pharmaceutical applications
samsung biologics (1)
Samsung Biologics completes Bioepis spinoff to become pure-play pharma CDMO
Eli Lilly the Netherlands Facility (1)
Lilly plans new oral medicine manufacturing plant in Europe
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE